Brainstem cholinergic modulation of muscle tone in infant rats.
In week-old rats, lesions of the dorsolateral pontine tegmentum (DLPT) and nucleus pontis oralis (PnO) have opposing effects on nuchal muscle tone. Specifically, pups with DLPT lesions exhibit prolonged bouts of nuchal muscle atonia (indicative of sleep) and pups with PnO lesions exhibit prolonged bouts of high nuchal muscle tone (indicative of wakefulness). Here we test the hypothesis that nuchal muscle tone is modulated, at least in part, by cholinergically mediated interactions between these two regions. First, in unanesthetized pups, we found that chemical infusion of the cholinergic agonist carbachol (22 mm, 0.1 microL) within the DLPT produced high muscle tone. Next, chemical lesions of the PnO were used to produce a chronic state of high nuchal muscle tone, at which time the cholinergic antagonist scopolamine (10 mm, 0.1 microL) was infused into the DLPT. Scopolamine effectively decreased nuchal muscle tone, thus suggesting that lesions of the PnO increase muscle tone via cholinergic activation of the DLPT. Using 2-deoxyglucose autoradiography, metabolic activation throughout the DLPT was observed after PnO lesions. Finally, consistent with the hypothesis that PnO inactivation produces high muscle tone, infusion of the sodium channel blocker lidocaine (2%) into the PnO of unanesthetized pups produced rapid increases in muscle tone. We conclude that, even early in infancy, the DLPT is critically involved in the regulation of muscle tone and behavioral state, and that its activity is modulated by a cholinergic mechanism that is directly or indirectly controlled by the PnO.
Gall
Andrew J
AJ
Program in Behavioral and Cognitive Neuroscience, Department of Psychology, University of Iowa, Iowa City, IA 52242, USA.
Poremba
Amy
A
Blumberg
Mark S
MS
D000109:Acetylcholine / Q000378:metabolism*; D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000779:Anesthetics, Local / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D001931:Brain Mapping; D002217:Carbachol / Q000494:pharmacology; D018679:Cholinergic Agonists / Q000494:pharmacology; D003847:Deoxyglucose / Q000378:metabolism; D004576:Electromyography; D007839:Functional Laterality; D008012:Lidocaine / Q000494:pharmacology; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009129:Muscle Tonus / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012601:Scopolamine / Q000494:pharmacology; D013681:Tegmentum Mesencephali / Q000187:drug effects / Q000378:metabolism*
D000779:Anesthetics, Local; D018679:Cholinergic Agonists; D018727:Muscarinic Antagonists; D002217:Carbachol; D008012:Lidocaine; D003847:Deoxyglucose; D012601:Scopolamine; D000109:Acetylcholine